Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Long-Term Investments (2022 - 2025)

Tarsus Pharmaceuticals has reported Long-Term Investments over the past 4 years, most recently at $3.9 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $3.9 million for Q4 2025, up 29.0% from a year ago — trailing twelve months through Dec 2025 was $3.9 million (up 29.0% YoY), and the annual figure for FY2025 was $3.9 million, up 29.0%.
  • Long-Term Investments for Q4 2025 was $3.9 million at Tarsus Pharmaceuticals, up from $3.0 million in the prior quarter.
  • Over the last five years, Long-Term Investments for TARS hit a ceiling of $3.9 million in Q4 2025 and a floor of $157000.0 in Q3 2022.
  • Median Long-Term Investments over the past 4 years was $1.8 million (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Long-Term Investments: surged 1328.57% in 2024 and later changed 0.0% in 2025.
  • Tarsus Pharmaceuticals' Long-Term Investments stood at $371000.0 in 2022, then skyrocketed by 70.08% to $631000.0 in 2023, then soared by 375.44% to $3.0 million in 2024, then rose by 29.0% to $3.9 million in 2025.
  • The last three reported values for Long-Term Investments were $3.9 million (Q4 2025), $3.0 million (Q3 2025), and $3.0 million (Q2 2025) per Business Quant data.